SCOTT KRUGER MD NPI 1376548057

NPI Details

Scott Kruger, MD is a hematology and oncology internal medicine in Hampton, VA with 41 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Scott Kruger, MD NPI is 1376548057. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: JEFFERSON MEDICAL COLLEGE OF THOMAS JEFFERSON UNIVERSITY
Graduation Year:1985

The provider's business location address is:

3000 COLISEUM DR
SUITE 104
HAMPTON, VA
ZIP 23666-963
Phone: (757) 827-9400
Fax: (757) 827-9320

The NPI 1376548057 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Protein measurement, serum (HCPCS:84165)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Vitamin d-3 level (HCPCS:82306)
• Blood test, clotting time (HCPCS:85610)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Folic acid level, serum (HCPCS:82746)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Unclassified drugs (HCPCS:J3490)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Magnesium level (HCPCS:83735)
• Urinalysis, manual test (HCPCS:81002)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Drawing of blood for a medical problem (HCPCS:99195)
• Injection of drug or substance into vein (HCPCS:96374)
• Administration of pneumococcal vaccine (HCPCS:G0009)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Injection, morphine sulfate, up to 10 mg (HCPCS:J2270)
• Pneumococcal vaccine, 23-valent (HCPCS:90732)

The enumeration date for this NPI number is 6/17/2005 and was last updated on 1/17/2019.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.